Thymoma staging: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
==Masaoka TNM Staging (1999)==
==Masaoka TNM Staging (1999)==
{|
{|
| [[File:T010.png|800px|thumb]]
| [[File:ttt1.png|800px|thumb]]
|}.<ref name="www.ncbi.nlm.nih.gov">{{Cite web  | last =  | first =  | title = Thymectomy and malignancy. [Eur J Cardiothorac Surg. 1994] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/8043287 | publisher =  | date =  | accessdate = }}</ref>
|}.<ref name="www.ncbi.nlm.nih.gov">{{Cite web  | last =  | first =  | title = Thymectomy and malignancy. [Eur J Cardiothorac Surg. 1994] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/8043287 | publisher =  | date =  | accessdate = }}</ref>



Revision as of 20:11, 20 February 2014

Thymoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thymoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thymoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymoma staging

CDC on Thymoma staging

Thymoma staging in the news

Blogs on Thymoma staging

Directions to Hospitals Treating Thymoma

Risk calculators and risk factors for Thymoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

  • There is no universally accepted system; no AJCC staging exists.
  • Historically, a classifiaction system used both histological features and clinical behavior.
  • Masaoka staging is the clinically used staging system, although it may not be predictive for thymic carcinoma.
  • GETT staging is the surgical staging system, and may have better correlation with outcome.
  • A meta-analysis from UCLA suggests that evaluation of transcapsular extension (Stage I vs. Stage IIa) is of no clinical value, as they have same DFS and OS outcomes.

Historical Classification

  • Benign Thymoma (histologically and behaviorally benign)
  • Malignant Thymoma (invasive)
  • Type I - histologically benign, but behaving aggressively with local invasion
  • Type II ("thymic carcinoma") - histologically malignant, aggresive behavior

Masaoka TNM Staging (1999)

.[1]


Original Masaoka Staging (1991)

  • Stage I - Macroscopically and microscopically completely encapsulated
  • Stage II - Macroscopic invasion into surrounding fatty tissues or mediastinal pleura or microscopic invasion into the capsule
  • Stage III - Macroscopic invasion into adjacent organs or intrathoracic metastases
  • Stage IVA - Pleural or pericardial implants/dissemination
  • Stage IVB - Nodal or hematogenous metastases

GETT Staging

  • Stage IA - Encapsulated, completely resected.
  • Stage IB - Macroscopically completely resected but suspicion of mediastinal adhesions or potential capsular invasion at surgery.
  • Stage II - Invasive tumor, completely resected.
  • Stage IIIA - Invasive tumor, subtotal resection.
  • Stage IIIB - Invasive tumor, biopsy alone.
  • Stage IVa - Supraclav or pleural met.
  • Stage IVb - Distant metastases.[1]

References

  1. 1.0 1.1 "Thymectomy and malignancy. [Eur J Cardiothorac Surg. 1994] - PubMed - NCBI".


Template:WikiDoc Sources